{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T13:18:44Z","timestamp":1779196724364,"version":"3.51.4"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,30]]},"abstract":"<jats:p>\n                    This study aims to investigate the relationship between serum calprotectin levels and different stages of multiple sclerosis (MS). This study was designed as a prospective, cross-sectional case-control study. A total of 98 patients diagnosed with relapsing-remitting MS and secondary progressive MS according to the 2017 McDonald criteria, along with 40 control patients whose human calprotectin levels were measured, were included in the study. The average age and human calprotectin levels in the patient group were found to be higher compared to the control group (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.013 and\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001, respectively). No significant differences were observed between groups for other parameters (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&gt;\u2005.05). A higher frequency of the relapsing-remitting MS type was observed in patients with a high calprotectin cutoff value within the patient group (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.035). Our study suggests the potential of serum calprotectin as a valuable biomarker in MS, both in aiding diagnosis and potentially distinguishing MS subtypes.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000046677","type":"journal-article","created":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T17:01:23Z","timestamp":1769965283000},"page":"e46677","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Human calprotectin as a novel biomarker in multiple sclerosis: Can it differentiate disease stages?"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0315-901X","authenticated-orcid":false,"given":"Elif Banu","family":"Soker","sequence":"first","affiliation":[{"name":"Department of Neurology, University of Health Sciences, Adana City Training and Research Hospital, Adana, Turkey."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8369-7816","authenticated-orcid":false,"given":"Miray","family":"Erdem","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Health Sciences, Adana City Training and Research Hospital, Adana, Turkey."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3567-1317","authenticated-orcid":false,"given":"Derya","family":"Ozdogru","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Health Sciences, Adana City Training and Research Hospital, Adana, Turkey."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9886-2017","authenticated-orcid":false,"given":"Yusuf","family":"Tamam","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Health Sciences, Adana City Training and Research Hospital, Adana, Turkey."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260519","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0074-7742(07)79005-0","article-title":"Immunopathogenesis of multiple sclerosis.","volume":"79","author":"Agrawal","year":"2007","journal-title":"Int Rev Neurobiol"},{"key":"R2-20260519","doi-asserted-by":"crossref","first-page":"a028936","DOI":"10.1101\/cshperspect.a028936","article-title":"Multiple sclerosis pathology.","volume":"8","author":"Lassmann","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"R3-20260519","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","article-title":"Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Neurology"},{"key":"R4-20260519","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jneuroim.2009.09.006","article-title":"Calprotectin levels in the cerebrospinal fluid reflect disease activity in multiple sclerosis.","volume":"216","author":"Berg-Hansen","year":"2009","journal-title":"J Neuroimmunol"},{"key":"R5-20260519","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/S0140-6736(00)03224-4","article-title":"Calprotectin, a faecal marker of organic gastrointestinal abnormality.","volume":"356","author":"Fagerhol","year":"2000","journal-title":"Lancet"},{"key":"R6-20260519","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1136\/adc.74.2.136","article-title":"Calprotectin as a marker of inflammation in cystic fibrosis.","volume":"74","author":"Golden","year":"1996","journal-title":"Arch Dis Child"},{"key":"R7-20260519","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/030097402320817077","article-title":"Leukocyte protein calprotectin and outcome in rheumatoid arthritis. A longitudinal study.","volume":"31","author":"Madland","year":"2002","journal-title":"Scand J Rheumatol"},{"key":"R8-20260519","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3109\/00365518409083820","article-title":"Plasma levels of the leucocyte L1 protein in febrile conditions: relation to aetiology, number of leucocytes in blood, blood sedimentation reaction and C-reactive protein.","volume":"44","author":"Sander","year":"1984","journal-title":"Scand J Clin Lab Invest"},{"key":"R9-20260519","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"key":"R10-20260519","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S1474-4422(15)00393-2","article-title":"MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines.","volume":"15","author":"Filippi","year":"2016","journal-title":"Lancet Neurol"},{"key":"R11-20260519","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.3389\/fimmu.2018.03116","article-title":"Pathogenic mechanisms associated with different clinical courses of multiple sclerosis.","volume":"9","author":"Lassmann","year":"2019","journal-title":"Front Immunol"},{"key":"R12-20260519","first-page":"527","article-title":"Progressive multiple sclerosis: from pathogenic mechanisms to treatment.","volume":"140","author":"Correale","year":"2017","journal-title":"Brain"},{"key":"R13-20260519","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1474-4422(13)70233-3","article-title":"Body fluid biomarkers in multiple sclerosis.","volume":"13","author":"Comabella","year":"2014","journal-title":"Lancet Neurol"},{"key":"R14-20260519","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/330080a0","article-title":"Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis.","volume":"330","author":"Odink","year":"1987","journal-title":"Nature"},{"key":"R15-20260519","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1189\/jlb.1008647","article-title":"The endogenous Toll-like receptor 4 agonist S100A8\/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer.","volume":"86","author":"Ehrchen","year":"2009","journal-title":"J Leukoc Biol"},{"key":"R16-20260519","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/labmed\/lmz003","article-title":"Serum S100A8\/A9 as a potentially sensitive biomarker for inflammatory bowel disease.","volume":"50","author":"Okada","year":"2019","journal-title":"Lab Med"},{"key":"R17-20260519","doi-asserted-by":"crossref","first-page":"102520","DOI":"10.1016\/j.msard.2020.102520","article-title":"Biomarkers of inflammation and epithelial barrier function in multiple sclerosis.","volume":"46","author":"Olsson","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"R18-20260519","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0304-3940(98)00263-8","article-title":"Serum levels of macrophage-derived protein MRP-8\/14 are elevated in active multiple sclerosis.","volume":"247","author":"Bogumil","year":"1998","journal-title":"Neurosci Lett"},{"key":"R19-20260519","doi-asserted-by":"crossref","first-page":"15367","DOI":"10.3390\/ijms242015367","article-title":"Elevated fecal calprotectin accompanied by intestinal neutrophil infiltration and goblet cell hyperplasia in a murine model of multiple sclerosis.","volume":"24","author":"Nouri","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R20-20260519","doi-asserted-by":"crossref","first-page":"181","DOI":"10.15324\/kjcls.2020.52.3.181","article-title":"Age-related fecal calprotectin concentrations in healthy adults.","volume":"52","author":"Park","year":"2020","journal-title":"Korean J Clin Lab Sci"},{"key":"R21-20260519","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3390\/sclerosis2030012","article-title":"Biomarkers differentiating RRMS and SPMS in multiple sclerosis\u2014a systematic review.","volume":"2","author":"Toftegaard","year":"2024","journal-title":"Sclerosis"},{"key":"R22-20260519","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.clim.2015.06.015","article-title":"Biomarkers in multiple sclerosis.","volume":"161","author":"Housley","year":"2015","journal-title":"Clin Immunol"},{"key":"R23-20260519","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1191\/1352458504ms1026oa","article-title":"Immunologic factors in primary progressive multiple sclerosis.","volume":"10","author":"Hohlfeld","year":"2004","journal-title":"Mult Scler"},{"key":"R24-20260519","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.4049\/jimmunol.1302884","article-title":"Comprehensive immunophenotyping of cerebrospinal fluid cells in patients with neuroimmunological diseases.","volume":"192","author":"Han","year":"2014","journal-title":"J Immunol"},{"key":"R25-20260519","first-page":"12","article-title":"Association between serum calprotectin expression and disease activity in patients with inflammatory bowel disease.","volume":"83","author":"Qian","year":"2021","journal-title":"Indian J Pharm Sci"},{"key":"R26-20260519","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1093\/brain\/awy151","article-title":"The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells.","volume":"141","author":"Machado-Santos","year":"2018","journal-title":"Brain"},{"key":"R27-20260519","doi-asserted-by":"crossref","first-page":"723009","DOI":"10.3389\/fneur.2021.723009","article-title":"Calprotectin in chronic inflammatory demyelinating polyneuropathy and variants-a potential novel biomarker of disease activity.","volume":"12","author":"Stascheit","year":"2021","journal-title":"Front Neurol"},{"key":"R28-20260519","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.2147\/NDT.S140634","article-title":"The role of microglia in multiple sclerosis.","volume":"13","author":"Luo","year":"2017","journal-title":"Neuropsychiatr Dis Treat"},{"key":"R29-20260519","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jneuroim.2003.11.005","article-title":"Monocyte activation and disease activity in multiple sclerosis. A longitudinal analysis of serum MRP8\/14 levels.","volume":"148","author":"Floris","year":"2004","journal-title":"J Neuroimmunol"},{"key":"R30-20260519","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1093\/brain\/awr182","article-title":"Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis.","volume":"134","author":"Howell","year":"2011","journal-title":"Brain"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046677","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T13:03:36Z","timestamp":1779195816000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046677","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"assertion":[{"value":"2025-05-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}